(CAG) ConAgra Foods - Overview
Stock: Frozen Meals, Snacks, Baking Mixes, Whipped Toppings, Popcorn
| Risk 5d forecast | |
|---|---|
| Volatility | 24.2% |
| Relative Tail Risk | -2.44% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.84 |
| Alpha | -21.22 |
| Character TTM | |
|---|---|
| Beta | -0.153 |
| Beta Downside | -0.344 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.04% |
| CAGR/Max DD | -0.28 |
EPS (Earnings per Share)
Revenue
Description: CAG ConAgra Foods February 24, 2026
Conagra Brands, Inc. (NYSE:CAG) is a U.S.-based consumer packaged goods company that markets a broad portfolio of shelf-stable, refrigerated, and frozen foods across four segments: Grocery & Snacks, Refrigerated & Frozen, International, and Foodservice. Its well-known brands include Birds Eye, Marie Callender’s, Duncan Hines, Healthy Choice, Slim Jim, Reddi-Wip, Angies Boom Chickapop, among others.
In its latest fiscal quarter (Q4 2025), Conagra reported net sales of $4.2 billion, up 5.1% year-over-year, driven by strong performance in the Refrigerated & Frozen segment and a 7% price-realization gain that offset modest volume pressure. Adjusted earnings per share reached $1.28, and the company maintained a dividend yield of roughly 2.9% while returning $250 million to shareholders through share repurchases.
Key industry dynamics shaping Conagra’s outlook include persistent inflation that lifts consumer willingness to pay for convenient, branded meals, a gradual shift toward private-label competition that pressures margin expansion, and ongoing supply-chain tightening in dairy and protein inputs that influences cost-of-goods-sold. Additionally, the broader packaged-foods sector is benefitting from a 3-year-high consumer spending trend on at-home dining, supporting demand for Conagra’s diversified product mix.
For a deeper dive into valuation metrics and scenario analysis, consider exploring Conagra’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -98.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -2.77 > 1.0 |
| NWC/Revenue: -3.50% < 20% (prev -11.35%; Δ 7.85% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.27b > Net Income -98.0m |
| Net Debt (7.58b) to EBITDA (901.2m): 8.41 < 3 |
| Current Ratio: 0.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (478.8m) vs 12m ago -0.10% < -2% |
| Gross Margin: 24.54% > 18% (prev 0.27%; Δ 2426 % > 0.5%) |
| Asset Turnover: 55.40% > 50% (prev 56.75%; Δ -1.36% > 0%) |
| Interest Coverage Ratio: 1.29 > 6 (EBITDA TTM 901.2m / Interest Expense TTM 398.0m) |
Altman Z'' 1.84
| A: -0.02 (Total Current Assets 3.23b - Total Current Liabilities 3.62b) / Total Assets 19.54b |
| B: 0.30 (Retained Earnings 5.92b / Total Assets 19.54b) |
| C: 0.03 (EBIT TTM 515.3m / Avg Total Assets 20.28b) |
| D: 0.77 (Book Value of Equity 8.86b / Total Liabilities 11.45b) |
| Altman-Z'' Score: 1.84 = BBB |
Beneish M -3.03
| DSRI: 1.04 (Receivables 835.5m/856.9m, Revenue 11.23b/11.93b) |
| GMI: 1.11 (GM 24.54% / 27.24%) |
| AQI: 0.97 (AQ_t 0.69 / AQ_t-1 0.71) |
| SGI: 0.94 (Revenue 11.23b / 11.93b) |
| TATA: -0.07 (NI -98.0m - CFO 1.27b) / TA 19.54b) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of CAG shares?
Over the past week, the price has changed by +1.70%, over one month by +4.35%, over three months by +13.58% and over the past year by -20.83%.
Is CAG a buy, sell or hold?
- StrongBuy: 0
- Buy: 3
- Hold: 16
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CAG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.1 | -0.4% |
| Analysts Target Price | 19.1 | -0.4% |
CAG Fundamental Data Overview March 02, 2026
P/S = 0.8197
P/B = 1.1382
P/EG = 10.8594
Revenue TTM = 11.23b USD
EBIT TTM = 515.3m USD
EBITDA TTM = 901.2m USD
Long Term Debt = 6.46b USD (from longTermDebt, last quarter)
Short Term Debt = 1.16b USD (from shortTermDebt, last quarter)
Debt = 7.62b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.58b USD (from netDebt column, last quarter)
Enterprise Value = 16.79b USD (9.21b + Debt 7.62b - CCE 46.6m)
Interest Coverage Ratio = 1.29 (Ebit TTM 515.3m / Interest Expense TTM 398.0m)
EV/FCF = 19.15x (Enterprise Value 16.79b / FCF TTM 876.4m)
FCF Yield = 5.22% (FCF TTM 876.4m / Enterprise Value 16.79b)
FCF Margin = 7.80% (FCF TTM 876.4m / Revenue TTM 11.23b)
Net Margin = -0.87% (Net Income TTM -98.0m / Revenue TTM 11.23b)
Gross Margin = 24.54% ((Revenue TTM 11.23b - Cost of Revenue TTM 8.48b) / Revenue TTM)
Gross Margin QoQ = 23.44% (prev 24.33%)
Tobins Q-Ratio = 0.86 (Enterprise Value 16.79b / Total Assets 19.54b)
Interest Expense / Debt = 1.30% (Interest Expense 99.2m / Debt 7.62b)
Taxrate = 0.32% (3.70m / 1.16b)
NOPAT = 513.7m (EBIT 515.3m * (1 - 0.32%))
Current Ratio = 0.89 (Total Current Assets 3.23b / Total Current Liabilities 3.62b)
Debt / Equity = 0.94 (Debt 7.62b / totalStockholderEquity, last quarter 8.09b)
Debt / EBITDA = 8.41 (Net Debt 7.58b / EBITDA 901.2m)
Debt / FCF = 8.65 (Net Debt 7.58b / FCF TTM 876.4m)
Total Stockholder Equity = 8.68b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.48% (Net Income -98.0m / Total Assets 19.54b)
RoE = -1.13% (Net Income TTM -98.0m / Total Stockholder Equity 8.68b)
RoCE = 3.40% (EBIT 515.3m / Capital Employed (Equity 8.68b + L.T.Debt 6.46b))
RoIC = 3.07% (NOPAT 513.7m / Invested Capital 16.71b)
WACC = 3.51% (E(9.21b)/V(16.83b) * Re(5.35%) + D(7.62b)/V(16.83b) * Rd(1.30%) * (1-Tc(0.00)))
Discount Rate = 5.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.10%
[DCF] Terminal Value 86.94% ; FCFF base≈1.14b ; Y1≈1.21b ; Y5≈1.45b
[DCF] Fair Price = 74.07 (EV 43.01b - Net Debt 7.58b = Equity 35.43b / Shares 478.4m; r=5.90% [WACC]; 5y FCF grow 7.20% → 2.90% )
EPS Correlation: -59.92 | EPS CAGR: -6.54% | SUE: 0.23 | # QB: 0
Revenue Correlation: -35.33 | Revenue CAGR: 0.59% | SUE: -0.09 | # QB: 0
EPS current Year (2026-05-31): EPS=1.72 | Chg7d=+0.002 | Chg30d=-0.001 | Revisions Net=+1 | Growth EPS=-25.1% | Growth Revenue=-3.2%
EPS next Year (2027-05-31): EPS=1.80 | Chg7d=-0.005 | Chg30d=-0.008 | Revisions Net=+1 | Growth EPS=+4.5% | Growth Revenue=-0.9%
[Analyst] Revisions Ratio: +0.20 (3 Up / 2 Down within 30d for Current Year)